Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Cited by
Items 101–200 of 648
Tumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
“Loeffler and colleagues, recently showed that CD8 T cell killing of fibroblasts, induced by FAP-specific DNA vaccination, was able to suppress primary tumor growth and metastases [142].”
BackgroundHu, S., Ma, J., Su, C., Chen, Y., Shu, Y., Qi, Z., Zhang, B., Shi, G., Zhang, Y., Zhang, Y., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.09.003 · Cited by 195
The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma
Sirica, A. E. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.222 · Cited by 188
The Role of the Tumor Microenvironment in the Progression of Pancreatic Cancer
Farrow, B., Albo, D., & Berger, D. H. (2008) · Journal of Surgical Research · doi:10.1016/j.jss.2007.12.757 · Cited by 186
“Key activators of tumorassociated fibroblasts have been identified in other cancers [106] and targeting killing of tumor associated fibroblasts decreased cancer cell growth and greatly increased intratumoral intake of chemotherapeutic drugs [107].”
BackgroundBrennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs336 · Cited by 188
Fibroblast activation protein: A potential therapeutic target in cancer
Liu, R., Li, H., Liu, L., Yu, J., & Ren, X. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.3.18696 · Cited by 182
“the animals completely rejecting a tumor cell challenge.(68) This strategy opens a new venue for the combination of immunotherapies and chemotherapies.”
BackgroundFibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma
Bughda, R., Dimou, P., D'Souza, R. R., & Klampatsa, A. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s291767 · Cited by 172
The dipeptidyl peptidase IV family in cancer and cell biology
Yu, D. M. T., Yao, T., Chowdhury, S., Nadvi, N. A., Osborne, B., Church, W. B., McCaughan, G. W., & Gorrell, M. D. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07526.x · Cited by 183
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Zhang, F., Ma, Y., Li, D., Wei, J., Chen, K., Zhang, E., Liu, G., Chu, X., Liu, X., Liu, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01600-2 · Cited by 212
“Researchers have developed DNA vaccines against the tumor stromal antigen FAP in primary tumors of colon and breast cancers in multidrug-resistant mice, which can effectively delay tumor proliferation and metastasis by killing and eliminating CAFs via CD8 + T cells [218].”
BackgroundVenook, A. P., Niedzwiecki, D., Lopatin, M., Ye, X., Lee, M., Friedman, P. N., Frankel, W., Clark-Langone, K., Millward, C., Shak, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1096 · Cited by 175
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
Targeting fibroblast activation protein in cancer ndash Prospects and caveats
Sedo, A. (2018) · Frontiers in Bioscience · doi:10.2741/4682 · Cited by 161
“Especially in highly desmoplastic tumors, FAP targeting may also improve the efficacy of conventional cytostatic agents by increasing their penetration into the tumor tissue (219) and reducing CAF functions (178).”
BackgroundWen, Y., Wang, C., Ma, T., Li, Z., Zhou, L., Mu, B., Leng, F., Shi, H., Li, Y., & Wei, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01695.x · Cited by 162
Antigens for cancer immunotherapy
Neller, M. A., López, J. A., & Schmidt, C. W. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.09.006 · Cited by 167
“[55] Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA.”
BackgroundFerreira, J. A., Peixoto, A., Neves, M., Gaiteiro, C., Reis, C. A., Assaraf, Y. G., & Santos, L. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.003 · Cited by 159
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 156
“FAP-based CAF-targeting therapeutic approaches using their neutralising antibodies [86–89], inhibitors [90–92], prodrugs [93,94] and DNA vaccine [81,95] showed attenuation in tumour growth via improving tumoural immune response in different”
BackgroundMethodInfluentialThe Role of Stroma in Tumor Development
Werb, Z., & Lu, P. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000127 · Cited by 176
“Blocking fibroblastactivating protein, which is made by carcinoma-associated fibroblasts, results in reduced type I collagen and improved drug delivery.(57)”
BackgroundTumor microenvironment for cancer stem cells
Kise, K., Kinugasa‐Katayama, Y., & Takakura, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.08.005 · Cited by 169
Design of nanocarriers based on complex biological barriers in vivo for tumor therapy
Liu, J., Li, M., Luo, Z., Dai, L., Guo, X., & Cai, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.010 · Cited by 157
Duperret, E. K., Trautz, A., Ammons, D., Perales-Puchalt, A., Wise, M. C., Yan, J., Reed, C., & Weiner, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2033 · Cited by 152
Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis
Madsen, C. D., Pedersen, J. T., Venning, F. A., Singh, L. B., Moeendarbary, E., Charras, G., Cox, T. R., Sahai, E., & Erler, J. T. (2015) · The EMBO Reports · doi:10.15252/embr.201540107 · Cited by 157
“Given that previous studies have successful eradicated subpopulations of CAFs and consequently improved the lifespan of tumour-bearing mice [48,49], we speculated whether deactivation of CAFs, by means of PHD inhibition, would have beneficial effects on tumour progression.”
Jolly, L. A., Novitskiy, S. V., Owens, P., Massoll, N. A., Cheng, N., Fang, W. B., Moses, H. L., & Franco, A. T. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2351 · Cited by 168
Exploring the Tumor Microenvironment with Nanoparticles
Miao, L., & Huang, L. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-16555-4_9 · Cited by 144
“Transient depletion of TAFs increased tumor permeability, suppressed IFP, increased NP accumulation, and inhibited tumor metastasis [50, 95, 147, 148].”
BackgroundFibrosis imaging: Current concepts and future directions
Baues, M., Dasgupta, A., Ehling, J., Prakash, J., Boor, P., Tacke, F., Kiessling, F. M., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.10.013 · Cited by 164
Zheng, H., Liu, H., Ge, Y., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02252-9 · Cited by 173
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
Dekker, T. J. A., van de Velde, C. J. �., van Pelt, G. W., Kroep, J. R., Julien, J. P., Smit, V. T. H. B. M., Tollenaar, R. A. �. �., & Mesker, W. E. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2571-5 · Cited by 167
“Other studies have implicated tumor-stroma in the promotion of resistance for systemic therapy [27].”
BackgroundSeprase: An overview of an important matrix serine protease
O’Brien, P., & O’Connor, B. F. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.01.006 · Cited by 170
“- 37 An important note from this article is that the DNA vaccine did not impair wound healing or damage normal tissue [111].”
BackgroundHeterogeneity of stromal fibroblasts in tumor
Orimo, A., & Weinberg, R. A. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.4.4255 · Cited by 143
ZI, F., HE, J., HE, D., LI, Y., YANG, L., & CAI, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3197 · Cited by 141
“This result is in accordance with evidence that an oral DNA vaccine targeting FAP α is able to suppress primary breast carcinoma growth and metastasis (28).”
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
Zhang, Q., Liu, R., Chan, K., Hu, J., Zhang, J., Wei, L., Tan, H., Yang, X., & Liu, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1314-9 · Cited by 148
“Cancer-associated fibroblasts (CAFs) are capable of decreasing drug uptake in tumors and causing resistance during chemotherapy [10].”
Yamaguchi, H., & Sakai, R. (2015) · Cancers · doi:10.3390/cancers7040876 · Cited by 148
“These results contradict other studies [54,59,60] and this discrepancy could be caused by the use of different animal models (e.”
ResultCombination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 148
“More importantly, different from tumor cells which are mutate frequently and genetically unstable, CAFs is geneticallymore stable,making them apreferable target for cancer therapy [210].”
BackgroundFibroblast Activation Protein-α
Kelly, T. J., Huang, Y., Simms, A. E., & Mazur, A. (2012) · International review of cytology · doi:10.1016/b978-0-12-394308-8.00003-0 · Cited by 158
Tumor microenvironment-mediated chemoresistance in breast cancer
velaei, K., Samadi, N., Barazvan, B., & Soleimani Rad, J. (2016) · The Breast · doi:10.1016/j.breast.2016.09.002 · Cited by 138
The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices
Senthebane, D., Jonker, T., Rowe, A., Thomford, N., Munro, D., Dandara, C., Wonkam, A., Govender, D., Calder, B., Soares, N., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102861 · Cited by 131
“Previous studies have shown that fibroblasts-secreted type I collagen, often upregulated in tumor microenvironments, can decrease chemotherapeutic drug uptake in cancer cells thus affecting the response of the cancer cells to the drugs [183,184].”
BackgroundChen, Y.-C., Lou, X., Zhang, Z., Ingram, P., & Yoon, E. (2015) · Scientific Reports · doi:10.1038/srep12175 · Cited by 136
Stroma in breast development and disease
Arendt, L. M., Rudnick, J. A., Keller, P. J., & Kuperwasser, C. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.003 · Cited by 134
“Anti-FAP antibodies have been engineered to deliver drugs to the tumor site, the serine-protease activity of FAP has been exploited to activate pro-toxins in the vicinity of the tumor, and vaccines have been developed to generate an immune reaction to the FAP antigen [96–98].”
BackgroundErnsting, M. J., Hoang, B., Lohse, I., Undzys, E., Cao, P., Do, T., Gill, B., Pintilie, M., Hedley, D., & Li, S.-D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.023 · Cited by 133
“Tumor-associated stroma is widely recognized as a target for therapy, both to normalize the microenvironment, and to reduce drug delivery barriers [3-9].”
BackgroundWang, S., Zhou, X., Xu, X., Ding, J., Liu, S., Hou, X., Li, N., Zhu, H., & Yang, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05470-5 · Cited by 133
Liu, C., Liu, L., Chen, X., Cheng, J., Zhang, H., Zhang, C., Shan, J., Shen, J., & Qian, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1236 · Cited by 139
CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?
Zhang, C., Fei, Y., Wang, H., Hu, S., Liu, C., Hu, R., & Du, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1113378 · Cited by 127
“In a pioneering investigation, an oral DNA vaccine targeting FAP targets was shown to drastically decrease primary tumor cell proliferation and neovascularization, considerably boost intra-tumor medication absorption, and minimize metastasis in colon and breast cancers by killing tumor-associated fibroblasts (Loeffler…”
BackgroundJia, D., Liu, Z., Deng, N., Tan, T. Z., Huang, R. Y.-J., Taylor-Harding, B., Cheon, D.-J., Lawrenson, K., Wiedemeyer, W. R., Walts, A. E., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.001 · Cited by 130
Li, M., Younis, M. H., Zhang, Y., Cai, W., & Lan, X. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05706-y · Cited by 140
“Targeting of FAP has been reported using a variety of approaches, including antibodies [17], vaccines [18], immunoconjugates [19], CAR T cells [20], peptide drug complexes [21], and FAP inhibitors (FAPI) [22, 23].”
BackgroundChronic Obstructive Pulmonary Disease: Epidemiology, Biomarkers, and Paving the Way to Lung Cancer
Szalontai, K., Gémes, N., Furák, J., Varga, T., Neuperger, P., Balog, J. Á., Puskás, L. G., & Szebeni, G. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132889 · Cited by 141
“Normalization of the tumor microenvironment through the therapeutic targeting of FAP-expressing cells has been successfully addressed in several studies using animal models [199,200].”
BackgroundMehraj, U., Ganai, R. A., Macha, M. A., Hamid, A., Zargar, M. A., Bhat, A. A., Nasser, M. W., Haris, M., Batra, S. K., Alshehri, B., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00634-9 · Cited by 143
Liu, Y., Sun, Y., Wang, P., Li, S., Dong, Y., Zhou, M., Shi, B., Jiang, H., Sun, R., & Li, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04080-z · Cited by 137
Regulation of tumor invasion by interstitial fluid flow
Shieh, A. C., & Swartz, M. A. (2011) · Physical Biology · doi:10.1088/1478-3975/8/1/015012 · Cited by 126
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice
Fang, J., Xiao, L., Joo, K., Liu, Y., Zhang, C., Liu, S., Conti, P. S., Li, Z., & Wang, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29831 · Cited by 120
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 145
Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma
Zhou, L., Yang, K., Andl, T., Wickett, R. R., & Zhang, Y. (2015) · Journal of Cancer · doi:10.7150/jca.10865 · Cited by 116
“As CAFs play an important role in tumor development and are more genetically stable than tumor cells, CAFs have been emerging as a promising therapeutic target for melanoma treatment [131].”
BackgroundCancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 136
“report that administration of a DNA vaccine inducing immunity against FAP (fibroblast activation protein), a protein overexpressed by CAFs, resulted in increased T-cell mediated killing of CAFs, reduced tumor growth, and improved survival in a murine model of colon and breast cancer [213].”
BackgroundOrigin and function of tumor stroma fibroblasts
Xouri, G., & Christian, S. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.11.017 · Cited by 137
Chan, T., Shaked, Y., & Tsai, K. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00688 · Cited by 132
“Along this line, an oral DNA vaccine targeting FAP, a CAF-specific marker, has been demonstrated to suppress tumor growth and metastasis and confer a survival benefit in murine models of CRC and breast cancer (92).”
BackgroundSalmonella typhimurium engineered to produce CCL21 inhibit tumor growth
Loeffler, M. W., Le'Negrate, G., Krajewska, M., & Reed, J. C. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0555-9 · Cited by 121
“Our data demonstrate that IV delivery of CCL21expressing attenuated S. typhimurium induces an inXammatory response within tumors and causes a substantial reduction of tumor burden in mice challenged with multidrugresistant CT26 colon, D2F2 breast, and B16 melanoma cells [ 26 ].”
BackgroundMethodInfluentialSelf-citationXiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 138
Kim, S. A., Lee, E. K., & Kuh, H. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.016 · Cited by 132
Shojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 131
Tchou, J., Zhang, P. J., Bi, Y., Satija, C., Marjumdar, R., Stephen, T. L., Lo, A., Chen, H., Mies, C., June, C. H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.06.016 · Cited by 112
“Unlike fibroblast-specific protein and other common fibroblastmarkers, FAP is a cell surface protein, rendering it a targetable molecule whereby novel therapeutic strategies that either (1) inhibit the FAP function (ie, protease activity) or (2) deplete cells that express FAP within the tumor microenvironment have sho…”
BackgroundAsgharzadeh, M. R., Barar, J., Pourseif, M. M., Eskandani, M., Jafari Niya, M., Mashayekhi, M. R., & Omidi, Y. (2017) · BioImpacts · doi:10.15171/bi.2017.15 · Cited by 115
Amornsupak, K., Insawang, T., Thuwajit, P., O-Charoenrat, P., Eccles, S. A., & Thuwajit, C. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-955 · Cited by 114
“Collagen type I secreted by fibroblasts can decrease chemotherapeutic drug uptake into cancer cells leading to the regulation of the response to several agents [17].”
BackgroundBoyd, L. N. C., Andini, K. D., Peters, G. J., Kazemier, G., & Giovannetti, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.006 · Cited by 119
Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand
Loeffler, M., Le’Negrate, G., Krajewska, M., & Reed, J. C. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn205 · Cited by 113
Self-citationKoczorowska, M. M., Tholen, S., Bucher, F., Lutz, L., Kizhakkedathu, J. N., De Wever, O., Wellner, U. F., Biniossek, M. L., Stahl, A., Lassmann, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.001 · Cited by 112
Cancer targeted therapeutics: From molecules to drug delivery vehicles
Liu, D., & Auguste, D. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.041 · Cited by 112
Wang, E., Wang, L.-C., Tsai, C., Bhoj, V. G., Gershenson, Z., Moon, E. K., Newick, K., Sun, J., Lo, A., Baradet, T. C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0054 · Cited by 121
Poggi, A., Varesano, S., & Zocchi, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00262 · Cited by 110
“However, FAP has been considered as a target for redirected T cells or chimeric antigen receptor (CAR) T cells (158, 159, 162) (Figure 3).”
BackgroundCan Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
Puré, E., & Lo, A. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0011 · Cited by 111
“An oral FAP vaccine suppressed primary tumor growth and metastasis in mouse models of colon and breast carcinoma (97).”
BackgroundZhu, Y., Li, X., Wang, L., Hong, X., & Yang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.988295 · Cited by 125
Surface-modified polymeric nanoparticles for drug delivery to cancer cells
Ahmed, A., Sarwar, S., Hu, Y., Munir, M. U., Nisar, M. F., Ikram, F., Asif, A., Rahman, S. U., Chaudhry, A. A., & Rehman, I. U. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1822321 · Cited by 122
Chen, H., Yang, W., Wen, Q.-T., Xu, L., & Chen, M. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.09.001 · Cited by 128
Chen, L., Li, J., Wang, F., Dai, C., Wu, F., Liu, X., Li, T., Glauben, R., Zhang, Y., Nie, G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1114 · Cited by 101
CXCL13-CXCR5 axis: Regulation in inflammatory diseases and cancer
Wang, B., Wang, M., Ao, D., & Wei, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188799 · Cited by 127
Jia, C., Wang, G., Wang, T., Fu, B., Zhang, Y., Huang, L., Deng, Y., Chen, G., Wu, X., Chen, J., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45446 · Cited by 106
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 120
“Collagen has also been linked to ECM stiffness [59] and, in support of this notion, depletion of the collagen I content in the tumor ECM increased intratumoral drug uptake and induced tumor shrinkage in breast or colon cancer-bearing mice [60].”
BackgroundErkan, M., Weis, N., Pan, Z., Schwager, C., Samkharadze, T., Jiang, X., Wirkner, U., Giese, N. A., Ansorge, W., Debus, J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-88 · Cited by 107
“It has been reported that experimental ablation of tumor associated fibroblasts or down-regulation of the hedgehog-signalling pathway in the pancreatic tumor stroma decreased cancer cell growth and greatly increased intra-tumoral uptake of chemotherapeutic drugs in murine models of colon, breast cancer an pancreatic c…”
BackgroundNiu, M., Naguib, Y. W., Aldayel, A. M., Shi, Y.-C., Hursting, S. D., Hersh, M. A., & Cui, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500565q · Cited by 111
Shahvali, S., Rahiman, N., Jaafari, M. R., & Arabi, L. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01308-9 · Cited by 118
“A threefold prolongation in lifespan and complete rejection of tumor cells by half of the animal population was also demonstrated [93].”
BackgroundLI, M., LI, M., YIN, T., SHI, H., WEN, Y., ZHANG, B., CHEN, M., XU, G., REN, K., & WEI, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4868 · Cited by 102
“…of the standard drugs for chemotherapy of colorectal cancer in clinical practice; however, there is a certain risk of drug resistance and tumor recurrence in patients treated with oxaliplatin (28,29), and a previous study demonstrated that these events may be associated with changes in CAFs (30).”
Cancer-Associated Fibroblasts as Targets for Immunotherapy
Kakarla, S., Song, X.-T., & Gottschalk, S. (2012) · Immunotherapy · doi:10.2217/imt.12.112 · Cited by 103
Baronzio, G., Parmar, G., & Baronzio, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00165 · Cited by 98
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 112
Dønnem, T., Al‐Saad, S., Al-Shibli, K. I., Delghandi, M. P., Persson, M., Nilsen, M. N., Busund, L., & Bremnes, R. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0414 · Cited by 112
Coto-Llerena, M., Ercan, C., Kancherla, V., Taha-Mehlitz, S., Eppenberger-Castori, S., Soysal, S. D., Ng, C. K. Y., Bolli, M., von Flüe, M., Nicolas, G. P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00979 · Cited by 99
Crosstalk between cancer‐associated fibroblasts and immune cells in cancer
An, Y., Liu, F., Chen, Y., & Yang, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14745 · Cited by 98
Dayer, C., & Stamenkovic, I. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.622274 · Cited by 106
“Targeting fibroblasts is thought to be a promising strategy in cancer treatment (37) because they are genetically stable, which reduces the likelihood of drug resistance, and because they are responsible for ECM properties that hamper diffusion of anticancer agents through solid tumors (36).”
BackgroundSignaling pathways in breast cancer: Therapeutic targeting of the microenvironment
Kamdje, A. H. N., Etet, P. F. S., Vecchio, L., Jm, M., Krampera, M., & Lukong, K. E. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.034 · Cited by 112
Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses
Li, J., Chen, D., & Shen, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869010 · Cited by 127
“Pre-clinical studies indicate that administration of DNA vaccine that targets FAP effectively depletes CAFs in the TME, and consequently suppresses CRC progression and metastasis (126).”
BackgroundStromal regulation of vessel stability by MMP14 and TGFβ
Sounni, N. E., Dehne, K., van Kempen, L., Egeblad, M., Affara, N. I., Cuevas, I., Wiesen, J., Junankar, S., Korets, L., Lee, J., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.003863 · Cited by 92
“Reduced type I collagen accumulation enhances drug penetration and drug responses (McKee et al., 2001; Brown et al., 2003; Loeffler et al., 2006; McKee et al., 2006), as does ectopic delivery of interstitial collagenases (Gade et al.”
InfluentialWen, X., He, X., Jiao, F., Wang, C., Sun, Y., Ren, X., & Li, Q. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14768383625385 · Cited by 100
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging
Peltier, A., Seban, R., Buvat, I., Bidard, F., & Mechta‐Grigoriou, F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.008 · Cited by 102
Hendrayani, S.-F., Al-Khalaf, H. H., & Aboussekhra, A. (2013) · Neoplasia · doi:10.1593/neo.13478 · Cited by 92
“Indeed, it has been shown that targeting CAFs improves cancer chemotherapy by increasing intratumoral drug uptake [33].”
BackgroundChen, B., Wang, Z., Sun, J., Song, Q., He, B., Zhang, H., Wang, X., Dai, W., & Zhang, Q. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.10.001 · Cited by 97
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery
Bouzin, C., & Féron, O. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.001 · Cited by 95
Cathepsin C is a tissue-specific regulator of squamous carcinogenesis
Ruffell, B., Affara, N. I., Cottone, L., Junankar, S., Johansson, M., DeNardo, D. G., Korets, L., Reinheckel, T., Sloane, B. F., Bogyo, M., et al. (2013) · Genes & Development · doi:10.1101/gad.224899.113 · Cited by 95
“Extracellular matrix (ECM) remodeling enzymes are well established as critical mediators of tissue homeostasis and pathogenesis in multiple diseases, most notably cancer (Egeblad and Werb 2002; Balkwill et al. 2005; van Kempen et al. 2006; Lopez-Otin and Matrisian 2007; Affara et al. 2009).”
BackgroundDrug resistance and tumor immune microenvironment: An overview of current understandings (Review)
Liu, Y., Liang, J., Zhang, Y., & Guo, Q. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5684 · Cited by 107
“Compared with the control group, the life span of the vaccinated mice was 3‑fold longer, and the tumor growth was significantly inhib‑ ited (209).”
BackgroundZou, A., Lambert, D., Yeh, H., Yasukawa, K., Behbod, F., Fan, F., & Cheng, N. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-781 · Cited by 93
“Targeting FAP expressing CAFs in animal models has been shown to inhibit growth of invasive tumors and enhance chemo-sensitivity to Doxorubicin in colon and breast cancers [26,27].”
BackgroundTruffi, M., Mazzucchelli, S., Bonizzi, A., Sorrentino, L., Allevi, R., Vanna, R., Morasso, C., & Corsi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061263 · Cited by 94
“A fortunate pre-clinical exception is the use of a DNA-based FAP vaccine, which showed an excellent anti-stromal CD8-mediated immunity, with subsequent restoring of chemosensitivity in a mouse model of breast cancer [92].”
Background
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.